Clinical utility of tafenoquine in the prevention of relapse of *Plasmodium vivax* malaria: a review on the mode of action and emerging trial data

Aurore B Hounkpatin1–3,*
Andrea Kreidenweiss1,2,*
Jana Held1–3

1Institute of Tropical Medicine, Eberhard Karls University Tübingen, Tübingen, Germany; 2German Centre for Infection Research, Partner Site Tübingen, Tübingen, Germany; 3Centre de Recherches Médicales de Lambaréné (CERME), Lambaréné, Gabon

*These authors contributed equally to this work

Abstract: Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of *Plasmodium vivax*, including dormant liver stages – so called hypnozoites. Its long half-life of ~15 days is allowing for a single exposure regimen. It has been under development since 1980 and received approval by the US Food and Drug Administration in summer 2018 as an anti-relapse drug for *P. vivax* malaria in patients aged 16 years and older and for prophylaxis of malaria caused by any *Plasmodium* species in adults. Prior to tafenoquine administration, glucose-6-phosphate dehydrogenase (G6PD) deficiency needs to be excluded by testing. Individuals with a deficient G6PD activity are at risk of tafenoquine-induced hemolysis – as is the case for primaquine, the mainstay drug for *P. vivax* radical cure.

A wealth of clinical studies have been conducted and are still ongoing to assess the safety, tolerability, and efficacy of tafenoquine. This review focuses on data emerging from the latest clinical trials on *P. vivax* radical cure with tafenoquine, the key studies for regulatory approval of tafenoquine, and elucidates the latest hypothesis on the mode of action.

Keywords: hypnozoite, 8-aminoquinoline, WR238605, radical cure

Introduction

Tafenoquine (TQ) is an 8-aminoquinoline derivative that had just received approval by the US Food and Drug Administration (FDA, July 2018) and the Australian Therapeutic Goods Administration (TGA, September 2018) for a radical cure of *Plasmodium vivax* malaria (US/Australia brand name Krintafel/Kozenis, developed by GlaxoSmithKline [GSK, London, UK]) together with Medicines for Malaria Venture (MMV, Geneva, Switzerland) and for prophylaxis of malaria (US/Australia brand name Arakoda/Kodatef, developed by 60 Degrees Pharmaceuticals (Washington DC, USA) together with the US Army). TQ passed more than four decades of development as an antimalarial drug, and was initially under investigation as a prophylactic antimalarial agent for preventing *Plasmodium falciparum* malaria but without final submission of the dossier for market authorization. Clinical development slowed down and only gained pace again in the last 10 years when containment and treatment of *P. vivax* malaria appeared on the WHO agenda.2 Preceding a neglected pathogen, *P. vivax* has received more attention in recent years. Due to its unique biologic features, *P. vivax* is nowadays considered a huge challenge for the control and elimination of malaria.3 *P. vivax* is globally the most widespread human malaria parasite species, and indeed causes more significant morbidity and mortality than previously thought.4 Unlike *P. falciparum*, *P. vivax* develops undetectable dormant liver stages (hypnozoites) in the infected host. These hypnozoites are spontaneously activated
by unknown mechanisms weeks (3–6 weeks) to several months (6–12 months) after the primary infection and cause blood stage infections called relapses, resulting in recurrent disease.5,6 As hypnozoites are not affected by standard antimalarial treatments, eg, chloroquine (CQ) or artemisinin based combination therapies (ACTs), the treatment is a particular challenge to \textit{P. vivax} malaria control.

Until FDA approval of TQ this summer, the only licensed drug for treatment of hypnozoites was primaquine (PQ), also an 8-aminoquinoline (8-AQ) known to act against dormant liver stages. It is given together with a 3-day treatment of CQ to provide radical cure, ie, curing the acute asexual blood stage infection and additionally clearing hypnozoites, thus preventing \textit{P. vivax} relapses.7–9 PQ side effects include gastrointestinal disturbances (GID), leukopenia, and methemoglobinemia (MHb).9 Of special concern is hemolysis in people with glucose-6-phosphate-dehydrogenase (G6PD)-deficiency, a genetic disorder frequently found in populations of malaria-endemic regions.7–10 This impedes PQ to be given without prior testing of the G6PD-status. In addition, PQ has to be metabolized by liver enzymes (CYP2D) to exert its action and will not be fully active in low metabolizers, leading to treatment failure.7,8 A major limitation is the short biological half-life (3–6 hours) of PQ, implying daily administration for 14 days, presenting a major issue for compliance.11

GSK supported by MMV were spearheading the recent TQ development program for a radical cure of \textit{P. vivax}. These efforts resulted into FDA approval of TQ as a single-dose (300 mg) oral treatment for \textit{P. vivax} hypnozoites in patients older than 16 years given together with appropriate acute \textit{P. vivax} antimalarial treatment (full course CQ or ACT).

TQ (2,6-dimethoxy-4-methyl-5-\{3trifluoromethyl\}-phenox)-8-\{4-amino-1-methylbutyl\}amino quinoline) (Figure 1) is a long-acting PQ analog active against both blood and liver stages of \textit{P. vivax} developed in the 1980s as an alternative to PQ by the Walter Reed Army Institute of Research in the USA, under the identifier WR238605.12,13 In total, 33 clinical studies with TQ as an anti-malarial agent have been conducted until October 2018. Results of the first TQ clinical trial in humans were published in 1998, showing that TQ was safe and well tolerated.14 The molecule’s promising half-life of 15 days initiated a series of clinical studies that led to established and consolidated safety, tolerability, and efficacy data.12,15–23

Three key studies with promising efficacy outcomes encouraged/fueled the current TQ anti-hypnozoite development program: DETECTIVE Part 1\textsuperscript{15} (phase II study) and Part 2 (NCT01376167, phase III study) and GATHER (NCT02216123, phase III study). Overall, TQ at a 300 mg single dose was highly efficacious in preventing \textit{P. vivax} recurrences until 6 months after treatment. In DETECTIVE Part 2, recurrence-free efficacy was 63% (95% CI = 55–69) for CQ + TQ, compared to 28% (95% CI = 20–36) for CQ alone. When CQ + TQ was compared to CQ + PQ, recurrence-free efficacy was 73% (95% CI = 65–79), compared to 75% (95% CI = 64–83), respectively.24

The aim of this review is to provide an update on what is known about the mode of action of TQ and to give an overview of the data emerging from the latest clinical trials conducted/being conducted in \textit{P. vivax} infected patients. Studies leading to approval of TQ as a prophylactic antimalarial drug against all \textit{Plasmodium} species are beyond the scope of this review, and will only be briefly summarized.

**Methods**

The literature databases NCBI PubMed and Cochrane Library, as well as the clinical trial registry databases ClinicalTrial.gov, FDA homepage fda.gov, and the WHO International Clinical Trial Registry Platform were searched. Search terms included tafenoquine, mode of action, clinical trials, human, \textit{P. vivax} malaria, and malaria in combination. The

![Figure 1 Chemical structure of tafenoquine.](https://www.dovepress.com/it/images/structure.png)
last search was done in October 2018. Any clinical trial on TQ was included, irrespective of study type. Data on two key studies (Detective Part II and Gather) are not yet published in peer-reviewed journals, but results were available through the FDA Application Review files available on the FDA webpage.

In total, 33 clinical studies on TQ were done or are still ongoing (Table 1). To date (October 2018) TQ has been evaluated in more than 4,000 individuals enrolled in ten phase I, nine phase II, eleven phase II/III, and three phase III clinical studies.

**Mechanism of action**

As is true for many antimalarial compounds, neither the exact mechanism of antiplasmodial activity of TQ nor of the much longer available/licensed drug PQ is well understood. TQ is active against both liver stages and blood stages of *P. vivax* and *P. falciparum*. Current hypotheses claim that different compound metabolites and, hence, different modes of action account for TQ’s parasite stage specific activity. As identified for PQ, CYP/CYP450 metabolism of TQ plays a crucial role for *P. vivax* liver stage activity, but seems not to be relevant for its blood schizonticidal activity.\(^{25}\) For PQ’s liver stage and anti-relapse activity liver enzyme CYP/CYP450 2D6 (CYP-2D6) metabolism is crucial. This was shown in transgenic mice that had a knockout of the P450 2D isozyme gene cluster. PQ was only active against *P. berghei* liver stages if the knockout was rescued with human CYP-2D6.\(^{26}\) This finding is completed by a report from a *P. vivax* human challenge trial, where two study participants experienced *P. vivax* relapses after CQ and PQ treatment, who were retrospectively identified as poor CYP-2D6 metabolizer genotypes.\(^{27}\)

The most likely mechanism of PQ’s antiparasitic activity is its metabolism via CYP-2D6 generating hydroxyl PQ metabolites. Redox cycling of these metabolites results in formation of reactive oxygen species leading to parasite death.\(^{28,29}\) The CYP-2D enzyme is highly polymorphic in human populations, and activity of the enzyme can be categorized in ultrarapid metabolizer, extensive metabolizer, intermediate metabolizer, and poor metabolizer.\(^{30,31}\) Frequencies of poor metabolizers vary between populations, but can be as high as 19%, in addition to poor metabolizers, also intermediate metabolizers might not be able to sufficiently metabolize the drug.\(^{25,32}\) Studies in the CYP-2D/human CYP-2D6 mice model indicated that CYP-2D metabolism is also crucial for TQ activation, although the extent of CYP-2D6 involvement in TQ liver stage efficacy is not clear.\(^{25,32}\) Indeed, evidence from human studies suggested that the mechanisms of TQ activation might be different. Retrospective analysis of CYP-2D6 genotypes in a phase Iib TQ trial did not reveal an effect on the anti-relapse efficacy of TQ nor

| **Title of publication or clinical trial** | **Study date** | **Reference** |
|-------------------------------------------|---------------|---------------|
| Assessment of any potential retinal effects of TQ | 2016–2017 | NCT02658435 |
| Application of the stable isotope label approach in clinical development-supporting dissolution specifications for a commercial tablet product with tafenoquine, a long half-life compound | 2016 | 78 |
| Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects | 2014–2015 | 55 |
| Hemolytic potential of tafenoquine in female volunteers heterozygous for G6PD deficiency (G6PD mahidol variant) vs G6PD-normal volunteers | 2009–2013 | 49 |
| Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects | 2011–2012 | 39 |
| Exposure-response analyses for tafenoquine after administration to patients with *Plasmodium vivax* malaria | 2011–2013 | 56 |
| Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects | 2009 | 45 |
| Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects | n.i. | 54 |
| Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure *vivax* malaria prophylaxis | 1999 | 43 |
| Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for *P. vivax* malaria radical cure | 1999–2000 | 41 |
| Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis | 1998–1999 | 79 |
| Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers | 1998–1999 | 53 |
| First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial | n.i. | 14 |

*Abbreviations: G6PD, glucose-6-phosphate dehydrogenase; n.i., not indicated; TQ, tafenoquine.*
on TQ pharmacokinetics, whereas these data further support the liability of CYP-2D6 metabolism of PQ for efficacy against hypnozoites.44 Despite its well described activity against *P. falciparum* and *P. vivax* blood stages, forming the rational for the prophylaxis development program, the mechanism of action is not known, but seems to be independent from the CYP-2D6 status.35 Potential mechanisms include interference with heme polymerization or oxidative mechanisms. In contrast to PQ, TQ is highly active against *Plasmodium* blood stages.34,36 Indeed in the mouse malaria model, TQ was 9-times more active than PQ against blood stages of drug-sensitive *P. berghei* strains.37 However, TQ is less active than CQ regarding the activity against blood stages of CQ-sensitive parasites.35 Currently the most likely explanation for PQ failures after a full treatment course (14 days) is rather based on polymorphisms of CYP-2D6 and mostly not resistance of the parasite to PQ.32

### Safety and tolerability

More than 4,000 participants received at least one dose of TQ, and safety and tolerability profiles were generally good. See Table 1 for an overview of studies with a particular focus on safety, tolerability, and pharmacokinetics, although safety was also studied and reported within efficacy trials (phase II and phase III). All studies were conducted in adults, except one that included children and young adults aged 12–20 years.17 The adverse event (AE) profile was similar between single dose and weekly or monthly treatments. Most of the AEs reported were mild and transient. Low doses of TQ (200 mg) were associated with fewer AEs compared to high doses (400, 500, and 600 mg).39 The most frequently reported AE was GID with diarrhea and abdominal pain.39–43 Pooled data of the three key studies for registration revealed that pruritus was the most frequent AE in participants exposed to CQ + TQ 300 mg single dose (37/317) followed by dizziness and nausea.44

AEs of special interest (AESIs) include cardiac, ophthalmic, and hematologic side effects, in addition to neurologic and psychiatric side effects, as these are known to be prevalent at various degrees for related drugs.

### Cardiac side effects

Cardiac effects of TQ were assessed in two studies with different doses (300, 450, 600, and 1,200 mg) given as monotherapy39,45 or in combination with CQ.45 No major clinical significant effect of TQ up to 1,200 mg on the QTcF was detected, and co-administration of TQ + CQ did not prolong the QT interval more than CQ monotherapy.

### Ophthalmic side effects

Eye disorders (mild vortex keratopathy, photophobia) were reported from one study in 69/74 (93%) Australian soldiers who received weekly TQ 200 mg for 6 months as a prophylactic regimen.40 The ophthalmic changes were not associated with visual disturbances or impaired acuity/color vision. The keratopathy resolved within 1 year in all cases (incidence at 3 month 39% and at 6 month 10%). Funduscopic assessments were made 3 months after the end of prophylactic treatment, and abnormalities were found in 27/69 individuals who took TQ and 4/17 individuals who took mefloquine. An independent group of experts investigated these findings and concluded that there is no sign of TQ-induced retinal toxicity. Induced ophthalmic changes are also known from other drugs, including the 4-aminoquinoline antimalarial CQ.46,47 Results of three following studies aimed to provide further evidence of the ophthalmic effects of TQ and did not find a clinically significant effect of TQ on ophthalmic function,19,41,45 even so a mild keratopathy was also observed with TQ when given for a short course (3 days).44 One unpublished study (NCT02658435) submitted with the dossier to FDA was a phase I study designed to investigate ophthalmic safety of the 300 mg TQ dose for radical cure. The study did not find a signal for retinal toxicity of this TQ dose.24 Ophthalmic safety will remain of special interest in future studies.

### Hematologic side effects

The main safety concern of TQ, like with other 8-AQ, is hemolysis in patients with G6PD-deficiency. G6PD-deficiency is frequently found in malaria endemic areas and is a hereditary, X-linked genetic defect so that males have either deficient G6PD activity (<30% of normal) or normal (>70% activity), whereas females can have intermediate (30%–60% activity) to deficient and normal activity.48

One study assessed the hemolytic risk of different doses of TQ (100, 200, and 300 mg) vs the standard 14-day regimen of PQ in healthy G6PD-deficient females with a G6PD enzyme activity of 40%–60% of the site median normal value in comparison to G6PD “normal” control individuals.49 Dose-limiting toxicity (≥2.5 g/dL decline in hemoglobin and ≥7.5% decrease in hematocrit vs pre-treatment) was reached in 3/3 individuals receiving TQ 300 mg and 3/5 individuals receiving PQ. Following these results, further female individuals with a higher enzyme activity (61%–80%) were recruited to receive a 200 mg dose of TQ. Only two individuals could be identified (six planned), both had lower hemolysis compared to the individuals with...
lower enzyme activity. Overall, hemolysis induced by TQ was higher in individuals with low G6PD-activity levels and increased with TQ dose. A TQ 300 mg single dose had similar hemolytic potential as PQ 15 mg for 14 days. All other clinical studies with TQ excluded individuals with a G6PD-activity <70%. Despite of this, eight incorrectly typed G6PD-deficient individuals were included in five clinical studies, all recovered without sequelae, but one individual experienced a serious adverse event (SAE), she was hospitalized and needed blood transfusion. These results further supported the contraindication of giving TQ to individuals with G6PD-activity <70%.

**Neurologic/psychiatric side effects**

Other clinical AEs that occurred with TQ administration were nervous and psychiatric disorders: insomnia, anxiety, depression, and mainly headache and dizziness. AEs were mild-to-moderate and transitional. 

**Serious adverse events**

In the three key studies, a total of 29 SAEs occurred in 483 individuals receiving CQ + TQ. Of those, hemoglobin (Hb) decrease was the most frequent SAE. An Hb decrease ≥30% or >39 g/L from baseline or a drop in Hb below 60 g/L was a predefined SAE described in the study protocol. The safety profile led to the addition of the following points to the prescribing information of TQ. G6PD testing has to be done in all individuals before prescription of the co-administered drug can be given without dose adjustment.

**Pharmacokinetics**

The pharmacokinetic profile of TQ was evaluated in several studies. TQ is slowly absorbed, with maximum plasma concentrations reached 12–16 hour post-administration. TQ has a large volume of distribution (~1,600 L), a long elimination half-life of 13–19 days, and is enriched in erythrocytes vs plasma. Administration of TQ with food increases adsorption and minimizes gastrointestinal side-effects. A population modeling approach combined data from different studies and showed that body weight, age, gender, and ethnicity did not have a large impact on pharmacokinetics. TQ pharmacokinetics were not affected by co-administration of commonly prescribed antimalarial drugs such as CQ or ACTs (dihydroartemisinin-piperaquine [DHA-PQP] or artemether-lumefantrine) so that TQ as well as the co-administered drug can be given without dose adjustment. The area under the curve (AUC) of TQ after a single dose of 300 mg TQ in adults is ~100 µg/mL and a Cmax of ~200 ng/mL. Modeling revealed that this dose (300 mg) would provide in 90% of individuals an AUC greater than 56.4 µg/h/mL – a concentration that was a significant breakpoint as a predictor of relapse to infection, so that individuals with a higher AUC have a high probability of being relapse-free at 6 months.

**Efficacy of TQ against P. vivax hypnozoites**

In July/September 2018, FDA/TGA approved TQ (Krintafel/Kodatef) for radical cure of P. vivax malaria administered as a 300 mg single dose together with a standard P. vivax antimalarial to patients ≥16 years. Three keys studies (DETECTIVE Parts 1 and 2, and GATHER) (NCT01376167, NCT02216123) provided evidence for efficacy and safety of this dose and led to dossier submission applying for registration.

In total, eight clinical studies investigated the anti-relapse efficacy of TQ in more than 2,700 adults ≥16 years with P. vivax malaria, of which more than 1,800 received TQ. Of these, 483 patients received a CQ (standard regimen)+TQ 300 mg single dose in three pivotal studies summarized below. All studies but one (7/8) randomized study participants, and 5/8 were multicentric studies (NCT02216123, NCT01376167). The anti-relapse efficacy of TQ was determined by assessing the proportion of overall recurrent P. vivax parasitemia in the Kaplan–Meier analysis at 6 months follow-up. All studies were conducted in malaria-endemic areas where P. vivax reinfections can occur. Unfortunately, for P. vivax no method is established to reliably distinguish relapses caused by hypnozoites from new infections. See Table 2 for an overview of clinical studies focusing on TQ efficacy for radical cure as well as for malaria prophylaxis.
**Table 2** List of clinical studies focusing on TQ efficacy

| Study drugs | Study type/endpoint(s) | Study period | Location | No. of participants | Sex/age | Infected on inclusion |
|-------------|------------------------|--------------|----------|---------------------|---------|----------------------|
| 1 TQ PQ DHA/PQP | Randomized, active-controlled, double-blind Efficacy/superiority of DHA/PQP vs PQ against DHA/PQP for *Plasmodium vivax* radical cure compared to CQ at 6 months after treatment | 2018 – 2019 | RC Timor-Leste | 150 planned | Males, females ≥18 years | Yes, *P. vivax* |
| 2 TQ PQ CQ | Active-controlled, double-blind Incidence of hemolysis, safety, and efficacy of TQ vs PQ for *P. vivax* radical cure at 6 months after treatment | 2015 – 2016 | RC Brazil Colombia Ethiopia Peru Thailand Vietnam | 251 included | Males, females ≥16 years | Yes, *P. vivax* |
| 3 TQ PQ CQ | Randomized, active-controlled, double-blind Effectiveness and safety of 300 mg TQ + CQ for *P. vivax* radical cure compared to CQ at 6 months after treatment | 2014 – 2016 | RC Bangladesh Brazil Cambodia Ethiopia India Peru Philippines Thailand | 522 included | Males, females ≥16 years | Yes, *P. vivax* |
| 4 TQ MQ PQ | Randomized, active-controlled, double-blind Efficacy of TQ for malaria prophylaxis for 6 months and for *P. vivax* post-exposure prophylaxis 3 months later | 2000 – 2001 | Pro, RC Timor-Leste | 654 included | Males, females 18–55 years | No |
| 5 (Doxy) TQ PQ | Randomized, open-label, parallel-group Efficacy of TQ for *P. vivax* post-exposure prophylaxis for 12 months | 1999 – 2000 | Pro Papua New Guinea Timor-Leste | 1,512 included | Males, females 18–55 years | No |
| 6 TQ | Randomized, placebo-controlled, double-blind, Long-term safety | 2017 – 2020 | Pro Australia | 600 planned | Males, females 18–55 years | NA |
| 7 TQ CQ | Open-label, non-comparative, single arm Pharmacokinetics, safety and efficacy of TQ in pediatric patients for *P. vivax* radical cure | 2017 – 2019 | RC Colombia Thailand Vietnam | 60 planned | Males, females 6 months–15 years | Yes, *P. vivax* |
| Treatment allocation | Status | Phase | Outcome | Reference |
|----------------------|--------|-------|---------|-----------|
| T1) DHA/PQP+TQ 300 mg (single dose)+PQ-placebo (for 14 days) T2) DHA/PQP+PQ 15 mg (for 14 days)+TQ-placebo T3) DHA/PQP+PQ-placebo (for 14 days)+TQ placebo | R      | III   | Study is ongoing | NCT02802501 |
| T1) CQ + TQ 300 mg (single dose)+PQ-placebo daily for 14 days T2) CQ + TQ placebo+PQ 15 mg daily for 14 days | C      | III   | Number (%) of recurrence-free participants at 6 months post-treatment: T1) CQ + TQ: 112/166 (76%) T2) CQ + PQ: 60/85 (71%) Overall incidence of clinically relevant hemolysis: T1) CQ + TQ: 2.4% T2) CQ + PQ: 1.2% | NCT02216123 (GATHER), 24 |
| T1) CQ + TQ 300 mg (single dose)+PQ-placebo daily for 14 days T2) CQ + TQ placebo+PQ 15 mg daily for 14 days T3) CQ + TQ placebo+PQ-placebo daily for 14 days | C      | III   | Number (%) of recurrence-free participants at 6 months post-treatment: T1) CQ + TQ: 155/260 (60%) T2) CQ + PQ: 83/129 (64%) T3) CQ: 35/133 (26%) | NCT01376167 (DETECTIVE, Part 2), 24 |
| T1) TQ loading dose 200 mg/day for 3 days followed by weekly dose of 200 mg TQ for 26 weeks T2) MQ loading dose 250 mg/day for 3 days followed by weekly dose of 250 mg MQ for 26 weeks Upon return to Australia: T1 received placebo twice a day for 14 days T2 received PQ 15 mg twice a day for 14 days | P      | III   | Malaria prophylaxis: number (%) of P. vivax uninfected participants at 6 months exposure: T1) 492/492 (100%) T2) 162/162 (100%) Post-exposure prophylaxis, number (%) of P. vivax uninfected participants at 3 months post-exposure: T1) 488/492 (99%) T2) 161/162 (99%) | 40, 80 |
| All study participants took doxy during their stay of at least 2 months in a malaria endemic region. The study started after their return and participants were randomized to 4 arms: T1) TQ 400 mg 1× daily for 3 days T2) TQ 200 mg 2× daily for 3 days T3) TQ 200 mg 1× daily for 3 days T4) PQ 7.5 mg 3× daily for 14 days+doxy 100 mg for 14 days | P      | II/III| Number (%) of P. vivax uninfected participants at 12 months post-exposure: T1): 223/242 (92%) T2): 156/161 (97%) T3): 386/406 (95%) T4): 429/464 (92%) Most common AEs were GID. Most AEs were mild or moderate | 19 |
| T1) TQ 200 mg/day for 3 days followed by TQ 200 mg 1× per week for 51 weeks T2) Placebo daily for 3 days followed by placebo 1× per week for 51 weeks | R      | II    | Study is ongoing | NCT03320174 |
| T1) CQ + TQ single dose (100–300 mg depending on weight) | R      | II    | Study is ongoing | NCT02563496 |

(Continued)
Table 2 List of clinical studies focusing on TQ efficacy

| Study drugs | Study type/endpoint(s)                                                                 | Study period | Location       | No. of participants | Sex/age                                      | Infected on inclusion |
|-------------|--------------------------------------------------------------------------------------|--------------|----------------|---------------------|----------------------------------------------|-----------------------|
| 8 TQ        | Randomized, double-blind, dose-ranging Optimal TQ dose, safety and tolerability, efficacy of TQ + CQ for P. vivax radical cure compared to CQ at 6 months after treatment | 2011 – 2013  | Brazil, Peru, India, Thailand | 329 included | Males, females/≥16 years                      | P. vivax              |
| CQ          |                                                                                      |              |                |                     |                                              |                       |
| PQ          |                                                                                      |              |                |                     |                                              |                       |
| 9 TQ        | Randomized, placebo-controlled, double-blind Efficacy and safety of TQ for treatment of P. vivax | 2003 – 2005  | Thailand       | 70 included         | Males, females/20–60 years                    | Yes P. vivax          |
| CQ          |                                                                                      |              |                |                     |                                              |                       |
| PQ          |                                                                                      |              |                |                     |                                              |                       |
| 10 TQ       | Randomized, placebo-controlled, double-blind Prophylactic efficacy of Plasmodium falciparum infection of TQ compared to MQ within 6 months | 2000 – 2003  | Kenya          | 306 included        | Males, females/18–55 years                   | No                    |
| MQ          |                                                                                      |              |                |                     |                                              |                       |
| 11 TQ       | Randomized, placebo-controlled, double-blind Prophylactic efficacy against P. falciparum infection of TQ compared to MQ during 17 weeks | 1998 – 2003  | Ghana          | 521 included        | Males/18–60 years and Females/50–60 years    | No                    |
| MQ          |                                                                                      |              |                |                     |                                              |                       |
| 12 TQ       | Randomized, double-blind Prophylactic efficacy against P. falciparum infection and safety of different doses of TQ | 1999         | Gabon          | 417 included        | Males, females/12–20 years                   | P. falciparum         |
| Treatment allocation | Status | Phase | Outcome | Reference |
|----------------------|--------|-------|---------|-----------|
| Single dose of each: |        |       |         |           |
| T1) CQ + TQ 50 mg    | P      | II    | Number (%) of recurrence-free participants at 6 months post-treatment: | 15 Part I of DETECTIVE |
| T2) CQ + TQ 100 mg   |        |       | T1) 29/55 (53%) |  |
| T3) CQ + TQ 300 mg   |        |       | T2) 29/57 (51%) |  |
| T4) CQ + TQ 600 mg   |        |       | T3) 48/57 (84%) |  |
| T5) CQ + PQ 15 mg over 14 days |        |       | T4) 43/56 (77%) |  |
| T6) CQ only          |        |       | T5) 34/50 (68%) |  |
|                      |        |       | T6) 21/54 (39%) |  |
| QT prolongation was the most common SAE: |        |       | 2% in TQ group |  |
|                      |        |       | 8% in PQ group |  |
|                      |        |       | 4% in CQ alone |  |
| AEs: Headache (28%), pyrexia (24%) and chills (23%), high incidence of diarrhea in T4 |        |       |  |  |
| T1) TQ 400 mg/day for 3 days, then PQ placebo from day 4 to day 18 | P      | II    | Number (%) of participants cured at day 28 after | 22 NCT02488980 |
| T2) CQ 1,000 mg on day 1 and day 2 and CQ 500 mg on day 3, then +TQ placebo on day 1 to day 3, then PQ 15 mg/day from day 4 to day 18 |        |       | T1) TQ: 40/43 (93%) |  |
| T3) Placebo for 3 days, then placebo weekly for 24 weeks | C      | II    | T2) CQ + PQ: 22/22 (100%) |  |
| T4) TQ 25 mg/day for 3 days, then TQ 25 mg weekly for 24 weeks |        |       | Number (%) of recurrence-free participants at 4 months after treatment start: |  |
| T5) Placebo, 6/99 (6%) |        |       | T1) TQ: 35/35 (100%) |  |
| T6) MQ 250 mg/day for 3 days, then MQ 250 mg weekly for 24 weeks |        |       | T2) CQ + PQ: 19/20 (95%) |  |
| T7) Placebo for 3 days, then placebo weekly for 24 weeks |        |       | Safety: 5 SAE in TQ group as increased MHb (related to drug) |  |
| T1) Placebo/day for 3 days, then placebo weekly for 13 weeks | P      | II    | Number (%) of P. falciparum uninfected participants within 6 months after treatment start: | 50 NCT02488980 |
| T2) TQ 25 mg/day for 3 days, then TQ 25 mg weekly for 13 weeks |        |       | T1) TQ: 12/102 (12%) |  |
| T3) TQ 50 mg/day for 3 days, then TQ 50 mg weekly for 13 weeks |        |       | T2) MQ: 7/99 (7%) |  |
| T4) TQ 100 mg/day for 3 days, then TQ 100 mg weekly for 13 weeks |        |       | T3) Placebo: 6/99 (6%) |  |
| T5) PQ 20 mg/day for 3 days, then PQ 20 mg weekly for 13 weeks |        |       | Safety and tolerability: musculoskeletal, GID and respiratory systems collectively accounted for 52%–70% of the total AEs in each group |  |
| T6) MQ 250 mg/day for 3 days, then MQ 250 mg for 13 weeks |        |       | 2% in CQ alone |  |
| T7) Placebo/day for 3 days, then placebo weekly for 13 weeks |        |       | 4% in PQ group |  |
| T1) TQ 250 mg/day for 3 days | P      | II    | Number (%) of P. falciparum uninfected participants within 17 weeks after treatment start: | 17 |
| T2) TQ 125 mg/day for 3 days |        |       | T1) Placebo: 9/94 (10%) |  |
| T3) TQ 62.5 mg/day for 3 days |        |       | T2) TQ 25 mg: 35/93 (38%) |  |
| T4) TQ 31.25 mg/day for 3 days |        |       | T3) TQ 50 mg: 78/91 (86%) |  |
| T5) Placebo/day for 3 days |        |       | T4) TQ 100 mg: 83/94 (88%) |  |
| T6) MQ 250 mg/day for 3 days, then MQ 250 mg for 13 weeks |        |       | T5) TQ 200 mg: 79/91 (87%) |  |
| T7) Placebo/day for 3 days, then placebo weekly for 13 weeks |        |       | T6) MQ: 40/46 (87%) |  |
| Abdominal was the most AE reported mainly in the TQ 250 mg group |        |       | 51% in TQ group |  |
| (Continued) |        |       | 39% in PQ group |  |
| 84% in TQ group |  | |
| 53% in MQ group |  | |
| 53% in CQ alone |  | |
| 53% in MQ group |  | |
| 39% in TQ group |  | |
| Study drugs | Study type/endpoint(s)                                                                 | Study period | Location | No. of participants | Sex/age                          | Infected on inclusion |
|------------|--------------------------------------------------------------------------------------|--------------|----------|---------------------|----------------------------------|----------------------|
| 13 TQ      | Randomized, placebo-controlled, double-blind prophylactic efficacy against P. falciparum infection of TQ compared to placebo within 17 weeks | 1997 – 1998  | Kenya    | 235 included        | Males, females/18–55 years       | No                   |
| 14 TQ/CQ   | Randomized, open-label, dose escalation, Safety, tolerability, and efficacy of TQ for P. vivax radical cure compared to CQ at 6 months after treatment | 1996 – 1997  | Thailand | 44 included         | Males, females/18–60 years       | P. vivax             |
| 15 TQ      | Randomized, placebo-controlled, double-blind Safety and prophylactic efficacy of TQ against P. vivax and drug-resistant P. falciparum infection | 1998         | Thailand | 205 included        | Males/18–55 years                | No                   |
| 16 TQ/PQ/CQ | Randomized, open-label Safety, tolerability, and efficacy of TQ for P. vivax radical cure | 1998 – 1999  | Thailand | 80 included         | Males, females/18–55 years       | P. vivax             |
| 17 TQ/CQ   | Open-label efficacy of TQ for P. vivax radical cure                                   | n.i.         | Australia| 27 included         | Males, females/mean age: 25 years | P. vivax             |
| Study          | Drugs   | Study type/endpoint | Study period | RC/Pro Location | No. of participants | Sex/age | Infected on inclusion | Treatment allocation | Status Phase | Outcome                                                                 | Reference |
|---------------|---------|---------------------|--------------|-----------------|--------------------|---------|----------------------|---------------------|--------------|---------------------------------------------------------------------------|-----------|
| 13            | TQ      | Randomized, placebo-controlled, double-blind | 1997–1998   | Pro Kenya       | 235                | Males, females/18–55 years | No              | T1) TQ 400 mg/day for 3 days, then placebo weekly for 13 weeks          | P II       | Number (%) of P. falciparum uninfected participants within 17 weeks after treatment start: T1) 38/54 (70%) T2) 46/53 (87%) T3) 51/57 (89%) T4) 5/59 (8%) Safety: AEs similar number of volunteers in the 4 treatment groups, GID more common in TQ 400 mg dose, 2 hemolytic events occurred in TQ recipients (G6PD status not been correctly checked) | 42        |
| 14            | TQ      | CQ*                 | 1996–1997   | Pro Thailand    | 44                 | Males, females/18–60 years | P. vivax       | T1) CQ + TQ 300 mg/day for 7 days T2) CQ + TQ 500 mg/day for 3 days T3) CQ + TQ 500 mg once T4) CQ only | P II       | Number (%) of recurrence-free participants at 6 months post-treatment: T1) 15/15 (100%) T2) 10/11 (90%) T3) 8/9 (89%) T4) 5/9 (56%) Safety/tolerability: Except of MHb elevations, no clinically important laboratory value abnormalities GID were slightly more frequent in the TQ groups than among the CQ group only | 21        |
| 15            | TQ      | Randomized, placebo-controlled, double-blind | 1998        | Pro Thailand    | 205                | Males/18–55 years         | No              | T1) TQ 400 mg/day for 3 days, then TQ 400 mg/month for 5 months          | P II       | Number (%) of P. falciparum and P. vivax uninfected participants at 6 months after TQ start treatment start: T1) 103/104 (99%) (1 vivax) T2) 71/101 (70%) (21 vivax, 8 falc, 1, mixed) Safety: GID more common among TQ recipients than among placebo recipients Most TQ recipients had transient, asymptomatic elevations of MHb | 23        |
| 16            | TQ      | CQa                 | 1998–1999   | Pro Thailand    | 80                 | Males, females/18–55 years | P. vivax       | T1) CQ + TQ 300 mg/day for 7 days T2) CQ + TQ 600 mg/day for 3 days T3) CQ + TQ 600 mg single dose T4) CQ only T5) CQ + PQ 15 mg/day for 14 days | P II       | Number (%) of recurrence-free participants at 6 months post-TQ treatment start: 26/27 (96%) T1) 18/18 (100%) T2) 19/19 (100%) T3) 17/18 (94%) T4) 5/13 (38%) T5) 9/12 (75%) Safety/tolerability: Transient elevations in the MHb, AEs among the treatment groups were mild and transient, higher proportion of GID among TQ recipients, no SAE | 20        |
|              | CQ      | Open-label          |             | Australia       | 27                 | Males, females/mean age: 25 years | P. vivax       | CQ: 600 mg+300 mg on day 1, 300 mg on day 2 and 300 mg on day 3 to treat acute infections Volunteers who already had ≥1 episode of P. vivax malaria relapse received TQ: TQ: TQ 200 mg/day for 3 days, then TQ 200 mg once/week for 8 weeks | P II       | Number (%) of recurrence-free participants at 6 months post-TQ treatment start: 26/27 (96%) No SAE, TQ was well-tolerated | 57        |

(Continued)
The following three key studies established 300 mg of TQ as an effective single dose treatment for radical cure of *P. vivax* malaria combined to CQ standard treatment.

DETECTIVE, Part 1 (NCT01376167), was a phase IIb/III dose-finding study conducted in four different countries (Brazil, Peru, India, and Thailand). Single doses of 50, 100, 300, or 600 mg TQ (combined to a standard regimen of 3 days CQ) were compared to 14 days PQ (15 mg/day) + CQ and CQ only. Of 329 participants enrolled, 225 received CQ + TQ. Recurrence-free efficacy 6 months after treatment with CQ + TQ 300 mg was 89% (95% CI = 77–95) compared to 38% (95% CI = 23–52) receiving CQ only and 77% (95% CI = 63–87) in the CQ + PQ group, corresponding to 48/57, 21/54, and 34/50 participants without a recurrence at 6 months, respectively. Recurrence-free efficacy at 6 months for the other doses was for CQ + TQ 50 mg 58% (95% CI = 43–70), and for CQ + TQ 100 mg 54% (95% CI = 40–66), and for CQ + TQ 600 mg 92% (95% CI = 80–97). Based on the safety and efficacy data from this study, TQ 300 mg was selected as the lowest efficacious dose for further evaluations in part 2 of DETECTIVE study.

DETECTIVE, Part 2 (NCT01376167), was a phase III study which confirmed efficacy of the selected TQ 300 mg single dose, and the study was conducted in Brazil, Peru, Colombia, Thailand, Philippines, and Ethiopia. Among the 522 included *P. vivax* malaria patients, recurrence-free efficacy at 6 months was for CQ + TQ 62% (95% CI = 55–69; n=155/260), for CQ + PQ 70% (95% CI = 60–77; n=83/129) and 28% (95% CI = 20–36; n=35/133) for CQ. GATHER (NCT02216123) was a phase III study conducted in Brazil, Colombia, Ethiopia, Peru, Thailand, and Vietnam to assess the effect of the single dose of 300 mg CQ + TQ and 14-day course of CQ + PQ on clinically relevant hemolysis defined as an Hb decrease of ≥30% or >30 g/L from baseline or an overall drop in Hb below 6 g/dL. Occurrence of clinically relevant hemolysis was similar between both groups: 2.4% for CQ + TQ vs 1.28% for CQ + PQ. The 6 months recurrence-free efficacy was similar between both regimens: 73% (95% CI = 65–79; n=112/166) for CQ + TQ and 75% for CQ + PQ (95% CI = 64–83; n=60/85).

These three studies showed an acceptable safety profile of the TQ 300 mg dose, when given together with CQ during a 6 month follow-up period and similar efficacy against recurrence for CQ + TQ compared to CQ + PQ.

### Supporting studies

Several additional trials have been conducted evaluating TQ efficacy against hypnozoites at different TQ doses and regimens (1-, 3-, and 7-day treatment). The findings of studies published until 2015 were summarized by a Cochrane review. A trial conducted in Thailand compared a high
single dose (600 mg) of TQ vs a 3-day regimen of daily 600 mg TQ or 7 days 300 mg TQ. Another study in Thailand tested a slightly lower single dose (500 mg) of TQ vs 3 days 500 mg TQ followed by the same dose (3 times 500 mg) 1 week later or vs 300 mg TQ given daily for 7 days. In both studies, TQ was compared to CQ alone and in the first study additionally to CQ + PQ. Data from these studies suggested that a single day treatment is sufficient to prevent *P. vivax* relapses. The rate of protection in the first study of the different TQ doses combined was 93% (95% CI = 7–99.9) and 91% in the second study (95% CI = 39–99). A third study performed in Thailand compared TQ 400 mg monotherapy (without CQ) for 3 days to CQ + PQ. This study revealed that monotherapy of TQ is efficacious, but parasite and fever clearance is slower compared to treatment with CQ, so that combination therapy should be given. Apart from one study where doxycycline was given with TQ, all participants were treated with a standard full course of CQ regimen (1,500 mg for 3 days) to treat the *P. vivax* infections. Pregnant/lactating women, children, individuals with G6PD-deficiency, or a mixed infection with malaria parasites other than *P. vivax* were not included in these studies.

In all these studies, activity against recurrences was evaluated without differentiating between relapse and new infection. Only samples of Detective Part 1 (NCT01376167) were additionally analyzed by a genotyping approach using three discriminatory markers. Recurrent infections that differed by at least one marker from pre-treatment infections were defined as heterologous. The authors suggested that analysis of the frequency of homologous and heterologous recurrences could be used for estimation of TQ's anti-hypnozoite efficacy against *P. vivax*, as they saw a dose response effect, ie, a reduction in homologous recurrences (probably relapses) at high doses of TQ, but not in heterologous recurrences (probably new infections). A separate analysis investigated, by mathematical modelling, the exposure response effect in time-to-recurrence of the infection. This revealed that a 300 mg dose led to a systemic exposure of TQ greater than AUC 56 µg/h/mL in 90% of individuals, an exposure that would lead to a significant lower 6 months recurrence rate.

Two studies assessing anti-recurrence efficacy are still ongoing: NCT02802501, a phase III study in Indonesia, testing the superiority of DHA + PPQ + TQ against DHA + PQ alone and DHA + PPQ + PQ for the prevention of *P. vivax* malaria recurrence at 6 months in 150 healthy adult volunteers; and NCT02563496, a phase II, prospective, open-label, multicenter, non-comparative, single arm study of children with *P. vivax* malaria in Colombia, Thailand, and Vietnam to the assess safety and efficacy of CQ + TQ single dose in a total of 60 pediatric individuals aged 6 months to <16 years.

### Prophylactic efficacy of TQ

In August 2018, the FDA also approved TQ, under the name ARAKODA, and shortly later Australia TGA, under the name KODATEF, for prophylaxis against all species of *Plasmodium* in patients aged 18 years and older for up to 6 months continuous dosing. For this indication, TQ was co-developed by the US Army and 60 Degrees Pharmaceuticals. The proposed prophylactic regimen is a loading dose of 200 mg once daily for 3 days before travel to a malaria endemic region, followed by a weekly 200 mg maintenance
dose during the stay and one final 200 mg dose in the week following exit from the malaria area.  

Several studies have been undertaken since the first trial done in 1998 showed a protection in three out of four individuals (75%) exposed to experimental infection with *P. falciparum* by mosquito bite after intake of a 600 mg single dose TQ. Since then, different doses and regimens have been evaluated that are nicely summarized in previous reviews. Five pivotal/key studies provided evidence for safety and prophylactic efficacy that led to drug approval: three phase II conducted in Africa (two in Kenya, one in Ghana), endemic for *P. falciparum* malaria, and one phase III prophylactic efficacy study in non-immune Australian soldiers deployed in East Timor.  

More than 1,250 adults, semi-immune and naïve, aged 18–55 years were included in the TQ prophylactic efficacy studies. The first time the now licensed prophylactic regimen (3 days 200 mg/day followed by weekly 200 mg) was given was in a study in Kenya comparing this regimen to 1) 3 days 400 mg/day followed by weekly placebo, 2) 3 days 400 mg/day followed by 400 mg weekly, and 3) placebo. After 13 weeks of prophylaxis in the placebo group, 54/94 had malaria, in group 1, only receiving a loading dose, 16/54 had malaria (68% protective efficacy), and similar efficacy was found between the 200 mg and 400 mg prophylactic regimen, with 7/53 and 6/57 acquiring malaria, respectively. As the 200 mg regimen was better tolerated, it was taken forward to the following studies, and the 200 mg regimen (n=492 individuals) was compared in a phase III trial to a standard regimen of mefloquine (162 individuals) in Australian soldiers going to East-Timor.  

No case of malaria occurred in both groups during the 6 months deployment. Another study in semi-immune adults from Ghana evaluated a 3-day loading dose with a following maintenance dose of TQ: 1) 25 mg, 2) 50 mg, 3) 100 mg, 4) 200 mg, vs 5) mefloquine 250 mg, or 6) placebo for 13 weeks. Results showed that 86/94 individuals were infected with malaria in the placebo group, for the regimen: 1) protective efficacy was 32% and 58/93 individuals got infected, whereas for PQ the threshold is >70%, whereas for PQ the threshold is >30%, therefore more individuals (usually females) will not be eligible to receive TQ treatment. A model was created by Watson et al estimating the number of individuals that will not be covered by PQ or TQ treatment due to their underlying genetic deficiency. Most available methods to test for the G6PD-deficiency status need trained staff and significant laboratory infrastructure, lacking at many field sites. The most frequently used method includes the fluorescent spot test, a semi-quantitative method based on UV spectrophotometry that can discriminate between normal (>70%) and the deficient malaria, a concentration that is usually reached with the now prescribed 200 mg regimen in 95% of individuals.  

Schizonticidal activity of TQ chemoprophylaxis against *P. falciparum* has been confirmed by a phase Ib double-blinded, placebo-controlled study in Australia. Two cohorts of eight healthy non-immune participants were assigned to either TQ 200 mg loading doses from day 1 to day 3 followed by another 200 mg on day 10 or placebo. Both groups were inoculated with –2,800 viable *P. falciparum* parasites on day 13. None of the TQ recipients, but all placebo recipients, developed parasitemia, confirming TQ’s schizonticidal activity.  

### Discussion  

Since 1950, PQ has been the drug of choice for treatment of the hypnozoites of *P. vivax* and *P. ovale*. Major shortcomings are PQ’s short half-life, implying a 14 day administration leading to poor compliance and a much lower effectiveness if applied in real life conditions. PQ is not safe in G6PD-deficient individuals, and has to be metabolized by cytochrome 2D6 to be active, a feature that is less pronounced in TQ. TQ is a long-awaited alternative drug to prevent *P. vivax* relapse that has been licensed after a long clinical development. The activity of TQ was superior to PQ against blood- and liver-stage parasites in vitro. The major advantage of TQ compared to PQ is its long half-life (2–3 weeks), allowing for a single dose regimen to clear hypnozoites. It is generally safe and well tolerated and clinical evidence shows that it is similarly efficacious as PQ against relapses of *P. vivax*. No effectiveness study has been conducted evaluating TQ and PQ in a real-life setting head to head. However, it is obvious that a single dose regimen will be superior, closing the efficacy–effectiveness gap.  

Hemolysis in G6PD-deficient individuals and formation of MHB remain the biggest restriction to the future usefulness of TQ. Especially in Asia, where *P. vivax* is most prevalent, a gene variant conferring severe G6PD-deficiency is frequent. TQ should be only given to individuals with a G6PD enzyme activity >70%, whereas for PQ the threshold is >30%, therefore more individuals (usually females) will not be eligible to receive TQ treatment. A model was created by Watson et al estimating the number of individuals that will not be covered by PQ or TQ treatment due to their underlying genetic deficiency. Most available methods to test for the G6PD-deficiency status need trained staff and significant laboratory infrastructure, lacking at many field sites. The most frequently used method includes the fluorescent spot test, a semi-quantitative method based on UV spectrophotometry that can discriminate between normal (>70%) and the deficient
status (<30%), but does not reliably determine the intermediate enzyme activities of heterozygous females. Reference testing for this includes flow cytometry to determine the fraction of G6PD-deficient erythrocytes in heterozygous females. The need of easy to use quantitative point-of-care tests has been realized, and several organizations (eg, PATH) support the development. A number of new point-of-care tests are in development and will likely facilitate accurate testing in the future.

Overall, the safety data of TQ are good, and higher doses than for PQ can be administered to most individuals, as TQ has a greater therapeutic window. However, here the longer half-life shows its disadvantage: G6PD-deficient individuals are at a potential greater risk of hemolysis, as active concentrations of TQ will remain in the body for several weeks, whereas the PQ course can be stopped if hemolysis aggravates. In addition, TQ shares the shortcoming of PQ that it cannot be given to pregnant or lactating women. Even though clinical infection with P. vivax is associated with maternal anemia and may be deleterious for the infant’s health, application is contraindicated in this group because of the danger of causing acute hemolytic anemia in the fetus. PQ can be given to children in a weight-adjusted dose. So far, the safety of TQ in children has not been established, but a pediatric trial is ongoing (NCT02563496), so that the indication will hopefully be expanded in future. Combination of TQ with other antimalarial drugs showed no major interactions, an important feature as combination therapy will be the choice for any future drug regimen, for acceleration of parasite clearance, but also for preventing the development of resistances.

Currently no other drug for hypnozoite treatment is in the drug development pipeline. The activity of antimalarial drugs against hypnozoite stages is only poorly understood and candidate drugs are scarce. This might be because, on the one hand, this stage is difficult to target as it is less metabolically active, and on the other hand because none of the Plasmodium parasite species that form hypnozoites can be kept in long-term continuous in vitro culture. In addition, in vivo and in vitro hypnozoite assays have only become available recently and are not yet implemented in a large scale in the malaria research community. Availability, simplification, and standardization of these assays might lead to new drug candidates for this indication that do not belong to the 8-aminoquinolines.

In addition to the application as a drug for radical cure against P. vivax hypnozoites, TQ also gained approval for chemical prophylaxis against infections of all Plasmodium species. Its long half-life allows for a once weekly regimen for this indication, whereas most other currently recommended prophylactic drugs need daily administration (doxycycline, atovaquone-proguanil) leading to poor compliance. Mefloquine can be given with a weekly dosing for malaria prophylaxis, but neurologic and psychiatric side effects have been associated with its use for prophylaxis, so that TQ might be a good alternative. Currently, TQ is licensed to be given for the duration of 6 months for prophylaxis. However, a current study is ongoing to evaluate the long-term safety of TQ when it is given as prophylactic regimen for 1 year (NCT03320174), specially focusing on the ophthalmic safety.

Conclusion
WHO recognized in its recent agenda that more attention has to be paid to P. vivax infections to move forward in the elimination efforts. Even though TQ does not overcome all shortcomings of PQ, the TQ single dose anti-relapse treatment for hypnozoites of P. vivax as well as of P. ovale advances the treatment regimens for these malaria species profoundly. The changes in the WHO agenda might have given the final impulse to keep TQ in the development pipeline and finally bring it to the market.

Currently no other drugs are in the pipeline with potential for anti-relapse therapy. Considering that development from the early clinical phase to market approval takes ~10 years, shows that no alternative to 8-AQ for anti-relapse therapy will be available in the near future. The present data suggest that TQ will replace current treatment regimens with PQ and play a major role in the treatment agenda for control and elimination of P. vivax malaria.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Frampton JE. Tafenoquine: first global approval. Drugs. 2018;78(14):1517–1523.
2. World Health Organization. World Malaria Report 2010. Available from: https://www.who.int/malaria/publications/atoz/9789241564106/en/. Accessed October 25, 2018.
3. Bassat Q, Velarde M, Mueller I, et al. Key knowledge gaps for Plasmodium vivax control and elimination. Am J Trop Med Hyg. 2016;95(6 Suppl):62–71.
4. World Health Organization. Control and elimination of Plasmodium vivax malaria: a technical brief; 2017. WHO. Available from: http://www.who.int/malaria/publications/world-malaria-report-2017/report/en/. Accessed June 8, 2018.
5. Mueller I, Galinski MR, Baird JK, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9(9):555–566.
6. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79–87.
25. Vuong C, Xie LH, Potter BM, et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59(7):3864–3869.

26. Pybus BS, Marcissen SR, Jin X, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12(1):212.

27. Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381–1382.

28. Idowu OB, Peggins JO, Brewer TG, Kelley C. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. Drug Metab Dispos. 1995;23(1):1–7.

29. Vásquez-Vivar J, Augusto O. Hydroxylated metabolites of the anti-malarial drug primaquine. Oxidation and redox cycling. J Biol Chem. 1992;267(10):6848–6854.

30. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689–723.

31. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYPD2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13.

32. Marcissen SR, Sousa JC, Reichard GA, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13(1):2.

33. Bernard S, Neville KA, Nguyen AT, Folckhart DA. Interethnic differences in genetic polymorphisms of CYPD2D6 in the U.S. population: clinical implications. Oncologist. 2006;11(2):126–135.

34. St Jean PL, Xue Z, Carter N, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYPD2D6 reduced metabolism is not associated with relapse in the phase 2B detecting trial. Malar J. 2016;15(1):97.

35. Vennerstrom JL, Nuzum EO, Miller RE, et al. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;43(3):598–602.

36. Robert A, Benoit-Vical F, Dechy-Cabaret O, Meunier B. From classical antimalarial drugs to new compounds based on the mechanism of action of artemisinin. Pure Appl Chem. 2001;73(7):1173–1188.

37. Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Antimicrob Agents Chemother. 1993;87(6):547–552.

38. August 24, 2018. FDA approves Arakoda for malaria prophylaxis in adults. Available from: https://www.healio.com/infectious-disease/emerging-diseases/news-online/%7b9bb8c1d6df6-0622-4fd6-b592-677747a75c0b%7d/fda-approves-arakoda-for-malaria-prophylaxis-in-adults. Accessed October 2, 2018.

39. Green JA, Patel AK, Patel BR, et al. Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol. 2014;54(9):995–1005.

40. Nasveld PE, Edstein MD, Reid M, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54(2):792–798.

41. Warrasak S, Euwwas A, Fukuda MM, et al. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. Int Ophthalmol. Epub 2018 Sep 29.

42. Shanks GD, Olool AO, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33(12):1968–1974.

43. Edstein MD, Nasveld PE, Kocisko DA, Kitchener SJ, Galton ML, Rieckmann KH. Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis. Trans R Soc Trop Med Hyg. 2007;101(3):226–230.

44. US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria | medicines for malaria venture. Available from: https://www.mmv.org/newsroom/press-releases/us-fda-approves-krintafel-tafenoquine-radical-cure-p-vivax-malaria. Accessed August 24, 2018.
45. Miller AK, Harrell E, Ye L, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013;76(6):858–867.

46. Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15(6):541–548.

47. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394.

48. Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Negl Trop Dis. 2018;12(4):e0006440.

49. Rueangweerayut R, Bancone G, Harrell EJ, Green JA, et al. Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers. Am J Trop Med Hyg. 2017;97(3):702–711.

50. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003;36(5):541–549.

51. Research C for DE and. Drug Approvals and Databases – Drug Trials Snapshots: KRINTAFEL. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ucm615729.htm. Accessed October 10, 2018.

52. Thakkar N, Green JA, Koh G, Dupare S, Tenero D, Goyal N. Population pharmacokinetics of tafenoquine, a novel antimalarial. Antimicrob Agents Chemother. 2018;62(11):2410 2018.

53. Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001;52(6):663–670.

54. Charles BG, Miller AK, Nasveld PE, Reid MG, Harris IE, Edstein MD. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother. 2007;51(8):2709–2715.

55. Green JA, Mohamed K, Goyal N, et al. Pharmacokinetic interactions between tafenoquine and dihydroartemisinin–piperaquine or artemether–lumefantrine in healthy adult subjects. Antimicrob Agents Chemother. 2016;60(12):AAC.01588-16–7332.

56. Tenero D, Green JA, Goyal N. Exposure-response analyses for Tafenoquine after administration to patients with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2015;59(10):6188–6194.

57. Kitchener S, Nasveld P, Edstein MD. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg. 2007;76(3):494–496.

58. Rajapakse S, Rodrigo C, Fernando SD. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2015 (4):CD010458.

59. Beck HP, Wampfler R, Carter N, et al. Estimation of the antirelapse efficacy of tafenoquine, using Plasmodium vivax genotyping. J Infect Dis. 2016;213(5):794–799.

60. Dow GS, Liu J, Lin G, et al. Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Malar J. 2015;14(1):473.

61. Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S. Tafenoquine for malaria prophylaxis in adults: an integrated safety analysis. Travel Med Infect Dis. 2017;17:19–27.

62. Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs. 2007;16(5):705–715.

63. McCarthy JS, Smith BL, Read LT, Dow LT. A randomized, double-blinded, placebo-controlled study in healthy, non-immune adults to determine the schizonticidal activity of tafenoquine after challenge with Plasmodium falciparum blood stage parasites. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372009. Published June 22, 2018. Accessed June 22, 2018.

64. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12(4):e0006230.

65. Ainoon O, Alawiyyah A, Yu YH, et al. Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient females. Southeast Asian J Trop Med Public Health. 2003;34(2):405–414.

66. Espino FE, Bibit JA, Sorruillo JB, Tan A, van Seidlein L, Ley B. Comparison of three screening test kits for G6PD enzyme deficiency: implications for its use in the radical cure of vivax malaria in remote and resource-poor areas in the Philippines. PLoS One. 2016;11(2):e0148172.

67. Bancone G, Kalnoky M, Chu CS, et al. The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects. Sci Rep. 2017;7(1):9822.

68. PATH. This blood test is the key to curing the most stubborn form of malaria. Available from: https://path.org/articles/blood-test-key-curing-most-stubborn-form-malaria/. Accessed December 5, 2018.

69. Pal S, Bansil P, Bancone G, et al. Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg. 2019;100(1):213–221.

70. Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J. 2017;16(1).

71. Bardaji A, Martinez-Espinosa FE, Arévalo-Herrera M, et al. Burden and impact of Plasmodium vivax in pregnancy: a multi-centre prospective observational study. PLoS Negl Trop Dis. 2017;11(6):e0005066.

72. Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in phase II clinical development. Expert Opin Investig Drugs. 2015;24(3):363–382.

73. Gural N, Mancio-Silva L, Miller AB, et al. In vitro culture, drug sensitivity, and transcriptome of Plasmodium vivax hypnozoites. Cell Host Microbe. 2018;23(3):395—406.

74. The malaria Refresher Consultative Panel on Basic Science and Enabling Technologies. malaERA: an updated research agenda for basic science and enabling technologies in malaria elimination and eradication. PLoS Med. 2017;14(11):e1002451.

75. March S, Ng S, Velmurgan S, et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe. 2013;14(1):104–115.

76. Mikolajczak SA, Vaughan AM, Kangwanrangsan N, et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe. 2015;17(4):526–535.

77. Medicines for Malaria Venture. MMV Annual Report 2016. Medicines for Malaria Venture. Available from: https://www.mmv.org/newsroom/publications/mmv-annual-report-2016. Published June 14, 2018. Accessed June 14, 2018.

78. Goyal N, Mohamed K, Rolfe K, et al. Application of the stable isotope label approach in clinical development - supporting dissolution specifica-

79. March S, Ng S, Velmurgan S, et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe. 2013;14(1):104–115.

80. Mikolajczak SA, Vaughan AM, Kangwanrangsan N, et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe. 2015;17(4):526–535.

81. Medicines for Malaria Venture. MMV Annual Report 2016. Medicines for Malaria Venture. Available from: https://www.mmv.org/newsroom/publications/mmv-annual-report-2016. Published June 14, 2018. Accessed June 14, 2018.

82. Goyal N, Mohamed K, Rolfe K, et al. Application of the stable isotope label approach in clinical development - supporting dissolution specifica-

83. March S, Ng S, Velmurgan S, et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe. 2013;14(1):104–115.
